Rani Therapeutics (RANI)
(Delayed Data from NSDQ)
$2.06 USD
-0.14 (-6.36%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $2.04 -0.02 (-0.97%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RANI 2.06 -0.14(-6.36%)
Will RANI be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for RANI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RANI
What Makes Rani Therapeutics Holdings, Inc. (RANI) a New Buy Stock
Rani Therapeutics Holdings, Inc. (RANI) Reports Q3 Loss, Lags Revenue Estimates
RANI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Rani Therapeutics Holdings, Inc. (RANI) Is a Great 'Buy the Bottom' Stock Now
Rani Therapeutics Holdings, Inc. (RANI) Reports Q2 Loss, Misses Revenue Estimates
Other News for RANI
Analysts Offer Insights on Healthcare Companies: Hoth Therapeutics (HOTH), Rewalk Robotics (LFWD) and Rani Therapeutics Holdings (RANI)
Buy Rating Maintained for Rani Therapeutics: A Financial and Risk Analysis Amidst Recent Equity Financing
Rani Therapeutics price target lowered by $4 at H.C. Wainwright, here's why
Analysts Conflicted on These Healthcare Names: Merus (MRUS), Staar Surgical (STAA) and Rani Therapeutics Holdings (RANI)
Analysts Offer Insights on Healthcare Companies: Outset Medical (OM), Rani Therapeutics Holdings (RANI) and Charles River Labs (CRL)